"Remain Encouraged by VBI-1901's Performance" - Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform with $8 Price Target

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $8.00 price target on VBI Vaccines (NASDAQ: VBIV), following the company's recent VBI-1901 data presentation.

The analyst comments: "As presented at a poster session, VBI-1901 showed favorable improvements in median overall survival (mOS) among patients with recurrent glioblastoma multiforme (GBM) when given with either of two adjuvants (GM-CSF, AS01B) relative to historical results for standard-of-care (chemo+Avastin). According to incremental Phase 2a results, the rate of 18-month overall survival in the GM-CSF arm (in which two partial responses had featured earlier in the study) was 25% (4/16) with mOS of 12.9 months. In the AS01B arm, 18-month OS was 40% (4/10) with mOS of 14.6 months, and included five patients who achieved stable disease (SD). As SOC imparts mOS of ~eight months, these results indicate nearly six months of additional survival benefit with '1901. We remain encouraged by VBI-1901's performance in this challenging malignancy, and look forward to the commencement of randomized controlled trials in 2H22."

For an analyst ratings summary and ratings history on VBI Vaccines click here. For more ratings news on VBI Vaccines click here.

Shares of VBI Vaccines closed at $0.89 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Freedom Broker Downgrades Holley (HLLY) to Hold
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell